Impact of a 12-week online wellness program in adults 50+ with chronic kidney disease

Study Lead

Dr. Puneeta Tandon

University of Alberta


Take a Step Towards Wellness. Join the 12-Week Program and Learn:

  • Tips from leading clinical experts
  • Why behaviour change is so hard
  • How to identify your values
  • The importance of goal setting
  • Techniques for self-compassion
  • The value of sleep
  • Strategies for managing thoughts and feelings

The time commitment varies depending on which arm of the program you are randomly assigned to. Because this is part of a research study, you will be randomly assigned to start the program right away, or in 12 weeks time. In order to register in the study, you must be available to start the day you are interested, or in 12 weeks time.

The EMPOWER program is 12 weeks long. You’ll be asked to complete the program for about 120 minutes each week. In addition to the program activities, you’ll also be asked to complete some surveys which will take about 45 minutes at the beginning and end of the program.

For more information, visit:


At this time, we’re testing this program in adults over the age of 50 living with chronic kidney disease.

Type of Participation

Focus Group


Chronic Kidney Disease


Quality of Life


All provinces and territories

Related studies

  • Take part in one hemodialysis session to evaluate Qidni Labs’ nearly waterless and portable dialysis system

    Overview: Qidni Labs is inviting up to 30 patients with kidney failure to take part in research studying the “Qidni/D”, an investigational hemodialysis device, as a possible treatment for kidney failure.

    Study type: Clinical Trial

    May 16, 2023

  • Person-centered integrated care delivery for patients with chronic kidney disease and multimorbidity in the primary care setting and primary-nephrology care interface

    Overview: Participants are invited to complete a 15-minute survey with questions about their experience with kidney care in Alberta.

    Study type: Survey

    May 16, 2023

  • Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE)

    Overview: The purpose of this study is to determine if spironolactone reduces death or hospitalization for heart failure and is well tolerated in patients that require dialysis.

    Study type: Clinical Trial

    April 28, 2023